Multiple Sclerosis Clinical Trial
— GE-O-VROfficial title:
The Effects of an Innovative Combined Virtual Reality and Robot Assisted Gait Training on Cognitive and Walking Functions in Patients With Multiple Sclerosis: A Randomized Control Trial
Multiple Sclerosis (MS), the most common non-traumatic cause of neurologic disability in
young adults, affects mobility and ambulation in the majority of patients. Nearly 50% of
persons with MS will require an assistive device to ambulate within 10 years of diagnosis. A
subgroup of MS is Primary Progressive MS, which manifests with gait disturbances over 80% of
patients in the long term. In addition to altered gait, nearly 70% of patients will
experience cognitive deficits during the course of the disease. Therefore, actions that
facilitate patient involvement in finding solutions for personalized management of disease
and disability are needed.
Although immunomodulatory drugs offer some benefit in other types of Multiple Sclerosis,
there is currently no effective treatment for Primary Progressive MS. A fundamental goal in
the management of persons with MS is to maximize their ability to ambulate and perform safe
and effective transfers in everyday life.
In the last decade, research has increasingly centered on the effects of robot devices in
the rehabilitation of patients with neurological diseases. This has led to the development
of new robot-assisted gait devices engendered by virtual-reality systems, and several
studies have demonstrated the positive effects that these devices have on gait endurance and
quality of life in patients with neurological diseases and disability.
The aim of this project is to develop and study the effects of a novel, cognitively
intensive virtual-reality -based rehabilitation software application that simulates a
real-world environment where a person can walk. The virtual-reality application is an
upgrade version synchronized to a robotic device, the GEO System. The second aim is to
compare the cognitive and motor effects of robot-assisted gait training with this
application against training with robot-assisted gait training without virtual reality.
The experimental group will receive robot-assisted gait training with the virtual-reality
application and the control group will receive robot-assisted gait training All subjects
will undergo training for 6 weeks (2 sessions/week) for a total of 12 sessions. Assessments
before training, after training, and at follow-up will be performed using clinical and
instrumental tests to compare the effects of training.
Successful completion of the study may help patients to alleviate the impact of disability,
increase their independence in activities of daily life, and improve their quality of life.
Through new rehabilitative strategies that combine cognitive and motor training involving
higher brain functions and motivation, patients will be stimulated to walk in a
reality-based environment.
Status | Not yet recruiting |
Enrollment | 20 |
Est. completion date | November 2018 |
Est. primary completion date | November 2017 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion Criteria: - Expanded Disability Status Scale between 3 and 6; - Mini Mental Examination State >24; - age >18 years; - ability to sit without trunk support; - ability to stand for at least 10 seconds with support; - no botulinum toxin injection into the affected leg muscles or rehabilitation treatment in the 6 months before recruitment. Exclusion Criteria: - patients with disease recurrence that has worsened significantly during the 8 weeks before recruitment; - changes in pharmacological therapy that could modify the disease course in the previous 3 months before recruitment; - changes in pharmacological therapy for fatigue treatment in the previous 3 months before recruitment - medications altering central nervous system (excitability (e.g., antiepileptics, neuroleptics, benzodiazepines or antidepressants) or with presumed effects on central nervous system plasticity (e.g., dopamine, fluoxetine or D-amphetamine); - other neurological or orthopedic conditions involving the lower limbs (musculoskeletal diseases, severe osteoarthritis, peripheral neuropathy, joint replacement); - cardiovascular co-morbidity (recent myocardial infarction, heart failure, uncontrolled hypertension, orthostatic hypotension). |
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Italy | Azienta Ospedaliera, SSO Rehabilitation Unit, Verona | Verona |
Lead Sponsor | Collaborator |
---|---|
Universita di Verona |
Italy,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | 10 meters Walking test (10-MtWT) change in gait speed (m/sec) | the test has been selected as a measure of gait speed. This is a validated test requiring individuals to walk on a flat hard floor at their fastest speed for 10 meters. Scoring is walking speed. | Baseline time 0 and up to 12 weeks | Yes |
Secondary | Berg Balance Scale | Baseline time 0 and up to 12 weeks | Yes | |
Secondary | 2-Minute Walking Test (meters) | Baseline time 0 and up to 12 weeks | Yes | |
Secondary | Activities-specific Balance Confidence Scale | Baseline time 0 and up to 12 weeks | Yes | |
Secondary | Tower of London - point | Tower of London assesses deficits in planning abilities and strategic problem solving. Two pictures are shown to the subject. Each picture shows three different colored balls arranged in different positions on three pegs. The subject has to transpose the three balls, starting from an initial position, to reach various final positions in a specific number of moves. The task comprises 12 problems with different target positions. For each problem, the participant earns three points if a solution is reached in only one attempt, two points if the solution is reached in two attempts, one point if the solution is reached in three attempts, and zero points if the solution is not reached in three attempts (range 0-36; higher scores=better performance) | Baseline time 0 and up to 12 weeks | Yes |
Secondary | Multiple Sclerosis Quality Of Life-54 | Baseline time 0 and up to 12 weeks | Yes | |
Secondary | Gait Analysis - Cadence (step/min) | It is an electronic system used for the gathering of the temporal-spatial data of deambulation. It is made up of an 8 meter long walkway connected to a computer. The system records the signal, reproducing the pressure maps of each step on video, identifying the progression of the center of gravity and recording all of the temporal-spatial features of gait. | Baseline time 0 and up to 12 weeks | Yes |
Secondary | Gait Analysis - Stride length (cm) | It is an electronic system used for the gathering of the temporal-spatial data of deambulation. It is made up of an 8 meter long walkway connected to a computer. The system records the signal, reproducing the pressure maps of each step on video, identifying the progression of the center of gravity and recording all of the temporal-spatial features of gait. | Baseline time 0 and up to 12 weeks | Yes |
Secondary | Gait Analysis - Step length (cm) | It is an electronic system used for the gathering of the temporal-spatial data of deambulation. It is made up of an 8 meter long walkway connected to a computer. The system records the signal, reproducing the pressure maps of each step on video, identifying the progression of the center of gravity and recording all of the temporal-spatial features of gait. | Baseline time 0 and up to 12 weeks | Yes |
Secondary | Gait Analysis - distance of heel to heel (cm) | It is an electronic system used for the gathering of the temporal-spatial data of deambulation. It is made up of an 8 meter long walkway connected to a computer. The system records the signal, reproducing the pressure maps of each step on video, identifying the progression of the center of gravity and recording all of the temporal-spatial features of gait. | Baseline time 0 and up to 12 weeks | Yes |
Secondary | Gait Analysis - time of stance (sec) | It is an electronic system used for the gathering of the temporal-spatial data of deambulation. It is made up of an 8 meter long walkway connected to a computer. The system records the signal, reproducing the pressure maps of each step on video, identifying the progression of the center of gravity and recording all of the temporal-spatial features of gait. | Baseline time 0 and up to 12 weeks | Yes |
Secondary | Gait Analysis - time of swing (sec) | It is an electronic system used for the gathering of the temporal-spatial data of deambulation. It is made up of an 8 meter long walkway connected to a computer. The system records the signal, reproducing the pressure maps of each step on video, identifying the progression of the center of gravity and recording all of the temporal-spatial features of gait. | Baseline time 0 and up to 12 weeks | Yes |
Secondary | Gait Analysis - time of single support (sec) | It is an electronic system used for the gathering of the temporal-spatial data of deambulation. It is made up of an 8 meter long walkway connected to a computer. The system records the signal, reproducing the pressure maps of each step on video, identifying the progression of the center of gravity and recording all of the temporal-spatial features of gait. | Baseline time 0 and up to 12 weeks | Yes |
Secondary | Gait Analysis - time of double support (sec) | It is an electronic system used for the gathering of the temporal-spatial data of deambulation. It is made up of an 8 meter long walkway connected to a computer. The system records the signal, reproducing the pressure maps of each step on video, identifying the progression of the center of gravity and recording all of the temporal-spatial features of gait. | Baseline time 0 and up to 12 weeks | Yes |
Secondary | Body's Centre of Pressure length (mm) | the static balance will be carried out with a monaxial platform, an electronic system used for the evaluation of the length of the centre of pressure (CoP) | Baseline time 0 and up to 12 weeks | Yes |
Secondary | Body's Centre of Pressure Area Path (mm2) | the static balance will be carried out with a monaxial platform, an electronic system used for the evaluation of the length of the centre of pressure (CoP) | Baseline time 0 and up to 12 weeks | Yes |
Secondary | Sustained Attention to Response Task - Time of reaction time | evaluates sustained attention, response inhibition, and reaction time. It is a go-no go target detection task composed of a series of numbers containing different digits from 1 to 9. The subject has to respond as quickly as possible to the appearance of each number by pressing a button, except when the number is 3. The score is the reaction times averaged over the test, and the total number of correct and incorrect responses | Baseline time 0 and up to 12 weeks | Yes |
Secondary | Phonemic Fluency Test | Baseline time 0 and up to 12 weeks | Yes | |
Secondary | Paced Auditory Serial Addition Test | Baseline time 0 and up to 12 weeks | Yes | |
Secondary | Trail Making Test | Baseline time 0 and up to 12 weeks | Yes | |
Secondary | Wechsler Adult Intelligence Scale | Baseline time 0 and up to 12 weeks | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05528666 -
Risk Perception in Multiple Sclerosis
|
||
Completed |
NCT03608527 -
Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis
|
N/A | |
Recruiting |
NCT05532943 -
Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis
|
Phase 1/Phase 2 | |
Completed |
NCT02486640 -
Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
|
||
Completed |
NCT01324232 -
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT04546698 -
5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
|
||
Active, not recruiting |
NCT04380220 -
Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
|
||
Completed |
NCT02835677 -
Integrating Caregiver Support Into MS Care
|
N/A | |
Completed |
NCT03686826 -
Feasibility and Reliability of Multimodal Evoked Potentials
|
||
Recruiting |
NCT05964829 -
Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis
|
N/A | |
Withdrawn |
NCT06021561 -
Orofacial Pain in Multiple Sclerosis
|
||
Completed |
NCT03653585 -
Cortical Lesions in Patients With Multiple Sclerosis
|
||
Recruiting |
NCT04798651 -
Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis
|
N/A | |
Active, not recruiting |
NCT05054140 -
Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT05447143 -
Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis
|
N/A | |
Recruiting |
NCT06195644 -
Effect of Galvanic Vestibular Stimulation on Cortical Excitability and Hand Dexterity in Multiple Sclerosis Patients
|
Phase 1 | |
Completed |
NCT04147052 -
iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis
|
N/A | |
Completed |
NCT03591809 -
Combined Exercise Training in Patients With Multiple Sclerosis
|
N/A | |
Completed |
NCT03594357 -
Cognitive Functions in Patients With Multiple Sclerosis
|
||
Completed |
NCT03269175 -
BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies
|
Phase 4 |